A detailed history of Profund Advisors LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 36,987 shares of BEAM stock, worth $935,401. This represents 0.03% of its overall portfolio holdings.

Number of Shares
36,987
Previous 30,868 19.82%
Holding current value
$935,401
Previous $723,000 25.31%
% of portfolio
0.03%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$22.57 - $33.14 $138,105 - $202,783
6,119 Added 19.82%
36,987 $906,000
Q2 2024

Aug 13, 2024

SELL
$21.22 - $32.66 $164,836 - $253,702
-7,768 Reduced 20.11%
30,868 $723,000
Q1 2024

May 08, 2024

SELL
$23.46 - $45.07 $392,485 - $754,021
-16,730 Reduced 30.22%
38,636 $1.28 Million
Q4 2023

Feb 14, 2024

SELL
$17.69 - $30.76 $34,513 - $60,012
-1,951 Reduced 3.4%
55,366 $1.51 Million
Q3 2023

Nov 13, 2023

BUY
$23.01 - $32.46 $233,850 - $329,890
10,163 Added 21.55%
57,317 $1.38 Million
Q2 2023

Aug 10, 2023

BUY
$29.32 - $35.99 $218,346 - $268,017
7,447 Added 18.75%
47,154 $1.51 Million
Q1 2023

May 11, 2023

BUY
$30.15 - $48.79 $952,408 - $1.54 Million
31,589 Added 389.12%
39,707 $1.22 Million
Q4 2022

Feb 02, 2023

BUY
$36.73 - $51.6 $6,207 - $8,720
169 Added 2.13%
8,118 $317,000
Q3 2022

Nov 04, 2022

BUY
$39.79 - $70.31 $51,607 - $91,192
1,297 Added 19.5%
7,949 $379,000
Q2 2022

Aug 01, 2022

SELL
$29.86 - $62.36 $13,884 - $28,997
-465 Reduced 6.53%
6,652 $257,000
Q1 2022

May 10, 2022

SELL
$53.73 - $82.16 $42,984 - $65,728
-800 Reduced 10.1%
7,117 $408,000
Q4 2021

Feb 08, 2022

SELL
$68.02 - $99.06 $43,804 - $63,794
-644 Reduced 7.52%
7,917 $631,000
Q3 2021

Nov 12, 2021

BUY
$84.37 - $133.6 $722,291 - $1.14 Million
8,561 New
8,561 $745,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.